T-Cell Project Awarded Major Funding

Kohanbash

Gary Kohanbash, assistant professor of neurological surgery and director of the Pediatric Neurosurgery ImmunoOncology Laboratory (PNIO) at the University of Pittsburgh, was one of four researchers awarded a total of $3 million by the Brain Tumor Funders’ Collaborative to help fund primary brain tumor immunotherapy research. Kohanbash’s project involves interrogating anti-tumor T-cells to develop adoptive cell transfer immunotherapy for pediatric high-grade gliomas.

Kohanbash and an interdisciplinary team of investigators at UPMC Children’s Hospital of Pittsburgh, UPMC Hillman Cancer Center, Children’s National and the University of California, San Francisco have developed a new method for identifying the most tumoricidal T-cell within a patient’s tumor. Using this approach, the team will isolate these T-cells from pediatric glioma and DIPG tumors, validate the safety and tumor-killing ability of these cells and develop a strategy for expanding these cells for re-infusion into patients.

If the project is successful, it could become a cutting edge, off-the-shelf approach in which a T-cell identified in one patient could be used to create T-cells that could kill tumors in a majority of patients with the similar disease. Long-term the approach could be used to develop a highly personalized strategy in which the most effective cytotoxic T-cells within each patient would be identified and used to creating millions of these as a therapy for that patient. Read more at neurosurgery’s website.